Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Mar 29:3:21-6.
doi: 10.2147/BCTT.S17108. eCollection 2011.

Cancer biomarker HER-2/neu in breast cancer in Indian women

Rajeev Singhai  1 , Amit V Patil  2 , Vinayak W Patil  1
Affiliations

Cancer biomarker HER-2/neu in breast cancer in Indian women

Rajeev Singhai et al. Breast Cancer (Dove Med Press). .

Retraction in

  • Retraction.
    [No authors listed] [No authors listed] Breast Cancer (Dove Med Press). 2012 Mar 8;4:33. doi: 10.2147/BCTT.S31163. eCollection 2012. Breast Cancer (Dove Med Press). 2012. PMID: 24367192 Free PMC article. No abstract available.

Abstract

Aim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.

Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.

Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.

Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.

Keywords: ER; PgR; breast cancer; hormone receptor; serum HER-2/neu receptor assay.

PubMed Disclaimer

References

    1. Coussens L, Yang-Feng TL, Liao YC, et al. Tyrosine kinase receptor with extensive homology to EGFR shares chromosomal location with neu oncogene. Science. 1985;230:1132–1139. - PubMed
    1. Slamon DJ, Clark GM. Amplification of c-erb-B2 and aggressive breast tumors. Science. 1988;240:1795–1798. - PubMed
    1. De Potter CR. The neu oncogene: more than a prognostic indicator. Hum Pathol. 1994;25:1264–1268. - PubMed
    1. Kurebayshi J. Biological and clinical significance of HER-2 overexpression in breast cancer. Breast Cancer. 2001;8(1):45–51. - PubMed
    1. Brandt-Rauf PW, Pincus MR, Carney WP. The c-erbB-2 protein in oncogenesis: molecular structure to molecular epidemiology. Crit Rev Oncog. 1994;5(2–3):313–329. - PubMed

Publication types